1Beumer HM,Olislagers WP,Kahn M,et al.Clinical evaluation of cefotiam and cefamandole in respiratory tract infections[J].Int J Clin Pharmacol Ther Toxicol,1985,23(2):105～108.
2B Watt,FV Brown.In-vitro activity of cefotiam against bacteria of clinical interest[J].J Antimicrob Chemother,1982,10(5):391～395.
3Tsuckiya K,M Kondo,Y Kita,et al.Absorptioh,distribution,and excretion of SCE-963,a new broad-spectrum cephalosporin:in mice,rats,rabbits,and dogs[J].J Antibiot,1978,31 (12):1272～1282.
4Lentino JR,M Stachowski,R Strikas,et al.Comparative efficacy of cefotiam versus cephalothin in the therapy of skin and soft tissue infections[J].Antimicrob Agents Chemother,1984,25 (6):778～780.
5Polism A,Tuazonc U.Cefotiam therapy of lower respiratory tract infections[J].Antimicrobial Agents and Chemotherapy,1985,28(4):576～577.
6Su-Ji Han,So-Yeon Jeong,Yun-Ju Nam,et al.Xylitol inhibits inflammatory cytokine expression induced by lipopolysaccharide from porphyromonas gingivalis[J].Clinical and Diagnostic Laboratory Immunology,2005,12(11):1285～ 1291.
4Pambor MA. p-phenetidine containing antioxidant as an occupa- tional eczematogenic agent in the manufacturing of special feed mixtures [ J ]. Berufsdermatosen, 1971 , 19 ( 6 ) : 285-991.
